Securing Access to Life-Saving Treatments: Enhancing Europe’s Critical Medicines Act for Rare Disease Communities

In recent years, the European Union (EU) has witnessed recurrent disruptions in the pharmaceutical supply chain, highlighting the urgent need for robust policies that guarantee access to critical medicines. While these shortages are detrimental to the general patient population, they pose a particularly severe threat to the rare disease community, whose treatments often rely on niche manufacturing processes with limited production capacity. Against this backdrop, the Securing Access to Life-Saving Treatments has emerged as a strategic initiative aimed at strengthening resilience in Europe’s pharmaceutical sector. The Act’s core objectives-such as mitigating overreliance on non-EU suppliers and establishing a secure framework for essential medicines-are commendable. Yet, RareGen Youth Network, an international youth-led NGO dedicated to empowering individuals with disabilities and rare diseases, proposes additional measures to maximize the Act’s impact and safeguard the needs of vulnerable populations.